Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Base-case analysis results (per patient)

From: Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran

Strategy name

Total costs ($)

Total QALYs

ICER (Cost per QALY)

Incremental costs ($)

Incremental QALYs

MPH

695

0.557

0

0

0

LDX

750

0.765

264.28

54.9

0.208

  1. LDX Lisdexamfetamine, MPH Methylphenidate
Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000